Overview

T2000 in Essential Tremor - Open Label Continuation

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.
Phase:
Phase 2
Details
Lead Sponsor:
Taro Pharmaceuticals USA